• Mitochondrial Apoptosis and Muscle Atrophy in Ovarian Cancer

  2026-05-30

  This study elucidates the distinct roles of mitochondrial-linked apoptosis and necroptosis in skeletal muscle wasting during ovarian cancer progression. Using a metastatic mouse model, the authors show that mitochondrial ROS-driven activation of apoptotic caspases is attenuated by SkQ1, but this does not prevent muscle atrophy, indicating that neither mitochondrial apoptosis nor necroptosis are causally linked to muscle loss in this context.

• HNF4A Hypermethylation Drives EMT in H. pylori-Linked Gastri

  2026-05-29

  This study uncovers how Helicobacter pylori infection leads to gastric cancer by triggering promoter hypermethylation and silencing of the tumor suppressor gene HNF4A, disrupting epithelial polarity and activating EMT signaling. These findings clarify a key epigenetic mechanism in gastric carcinogenesis and open avenues for targeted epigenetic intervention.

• HyperFluor™ 488 Goat Anti-Rabbit IgG (H+L): Technical Use Gu

  2026-05-29

  The HyperFluor™ 488 Goat Anti-Rabbit IgG (H+L) Antibody addresses the need for sensitive, specific fluorescent detection of rabbit primary antibodies in immunofluorescence, microscopy, and flow cytometry. It should be used where robust signal amplification and low cross-reactivity are critical, but is not suitable for non-rabbit primaries or applications incompatible with sodium azide or glycerol.

• Iptacopan (LNP023): Precision Control of the Alternative Com

  2026-05-28

  Explore how Iptacopan (LNP023) enables unprecedented selectivity in alternative complement pathway research, with detailed mechanistic insights and practical assay guidance. This article uniquely connects molecular pharmacology to advanced animal modeling, optimizing translational outcomes.

• Angiotensin II in Vascular Remodeling: Workflow & Troublesho

  2026-05-28

  Angiotensin II (Asp-Arg-Val-Tyr-Ile-His-Pro-Phe) is the gold-standard tool for dissecting hypertension mechanisms and vascular smooth muscle cell hypertrophy in both cell culture and animal models. This article delivers actionable, protocol-focused insights and troubleshooting strategies to optimize experimental outcomes using APExBIO’s validated Angiotensin II peptide.

• AG-221 (Enasidenib): Optimizing IDH2-Mutant AML Research Wor

  2026-05-27

  AG-221 (Enasidenib) is the benchmark for targeting mutant IDH2 in acute myeloid leukemia (AML), enabling precise 2-hydroxyglutarate reduction and robust leukemic cell differentiation. This guide translates the latest metabolic rewiring insights into actionable protocols, troubleshooting, and integration strategies for advanced disease modeling and resistance studies.

• Patient-Derived Gastric Cancer Assembloids Advance Drug Test

  2026-05-27

  The referenced study introduces a patient-specific gastric cancer assembloid model that integrates matched tumor organoids with stromal cell subpopulations, enabling more physiologically relevant drug sensitivity and resistance profiling. This approach addresses limitations of conventional organoid models and offers a robust platform for personalized cancer therapy development.

• S-Adenosylhomocysteine: Mechanisms, Evidence, and Workflow I

  2026-05-26

  S-Adenosylhomocysteine (SAH) is a central regulator of methylation cycles and metabolic pathways. Its precise role in methyltransferase inhibition and SAM/SAH ratio modulation is essential for cellular homeostasis and disease models. This article distills evidence-based insights, protocol parameters, and misconceptions to optimize SAH use in research.

• Synergistic Inhibition of Terminal Oxidases in Tuberculosis

  2026-05-26

  The referenced study uncovers that pretomanid, a bicyclic nitroimidazole derivative, exerts bactericidal effects against Mycobacterium tuberculosis by simultaneously targeting both cytochrome bcc:aa3 and bd oxidases, disrupting bacterial respiration. This dual-inhibition strategy not only potentiates drug synergy with agents like telacebec but also suppresses resistance, informing rational design of future tuberculosis drug regimens.

• Perifosine (KRX-0401): Strategic Integration in Translationa

  2026-05-25

  Explore how Perifosine (KRX-0401), a synthetic alkylphospholipid Akt inhibitor, enables translational researchers to interrogate apoptosis and radiosensitization mechanisms in cancer and neuroprotection models. This article delivers mechanistic insights, evidence-backed protocol parameters, and a forward-looking perspective on leveraging Perifosine to advance experimental oncology and beyond.

• G007-LK: Driving Translational Breakthroughs in Tankyrase-Ta

  2026-05-25

  This thought-leadership article explores the mechanistic, experimental, and strategic landscape of G007-LK, a potent tankyrase 1/2 inhibitor, with a focus on its transformative role in Wnt/β-catenin signaling pathway inhibition, β-catenin degradation, and clinical impact in APC mutation colorectal cancer and hepatocellular carcinoma (HCC) research. We synthesize evidence from primary literature and recent workflow guides, highlight advanced protocol parameters, and challenge the boundaries of translational research tool commentary. Readers will gain actionable insights for integrating G007-LK into high-impact oncology pipelines and a visionary outlook on the future of tankyrase inhibition.

• Cdk5 Downregulation Alleviates Neuronal Ferroptosis via AMPK

  2026-05-24

  This study demonstrates that inhibiting Cdk5 mitigates hippocampal neuron ferroptosis and neuroinflammation after ischemic stroke, primarily through modulation of the AMPK pathway and microglial polarization. The findings highlight a potential therapeutic axis for reducing neuronal damage in stroke and provide a mechanistic basis for targeting iron-dependent cell death.

• 10058-F4 c-Myc-Max Dimerization Inhibitor: Applied Workflows

  2026-05-23

  10058-F4 enables precise disruption of oncogenic c-Myc-Max interactions, empowering apoptosis and leukemia research with robust, reproducible protocols. Explore advanced workflow optimizations, troubleshooting strategies, and the translational impact of c-Myc inhibition informed by the latest findings on DNA repair and telomerase regulation.

• Verteporfin: Applied Workflows in Photodynamic Therapy & Ass

  2026-05-22

  Verteporfin (CL 318952) from APExBIO empowers researchers with dual-action capabilities for targeted photodynamic therapy and light-independent autophagy inhibition. This article delivers stepwise protocols, advanced troubleshooting, and actionable insights on maximizing data quality and reproducibility in ocular neovascularization and cell fate studies.

• HRP Goat Anti-Rabbit IgG (H+L) Antibody: Technical Usage Gui

  2026-05-22

  The HRP Goat Anti-Rabbit IgG (H+L) Antibody addresses the need for high-specificity secondary antibody detection of rabbit IgG in immunoassays such as Western blot, ELISA, IHC, and IC. It should be used strictly for research applications involving rabbit-derived primaries and is not recommended for diagnostic, therapeutic, or non-rabbit targets.

15900 records 1/1060 page Next 12345 下5页 Last page